NEWS CENTER

Introduction

In 2026, “Who supplies our gloves?” is no longer a simple line-item question. For hospitals and health systems worldwide, exam and specialty gloves sit at the intersection of infection prevention, staff comfort, regulatory documentation, and supply-chain resilience.

This guide is built to help you make supplier decisions that hold up under audit pressure and disruption—not just when markets are calm. You’ll learn how the vendor ecosystem is structured, which compliance anchors matter most, how sourcing channels (including distributor networks and group purchasing arrangements) change your real options, and how to think about resilience and total cost of ownership (TCO) beyond unit price.

If you support procurement, supply chain, materials management, or infection prevention, use this as a qualification lens for medical glove suppliers and as a shared vocabulary for clinical + sourcing teams.

Regional compliance note

Medical gloves are regulated differently across regions. This guide prioritises publicly verifiable evidence (official product pages, certificates, and regulator databases where accessible). Always confirm requirements for your market (e.g., device classification, labelling, sterility validation, and any premarket notification/registration rules) using your local regulator’s guidance and your facility’s policies.

Quick shortlist scorecard (backed by evidence)

Use this table to compare suppliers consistently. Scores should be backed by links to evidence (official product pages, certifications/quality statements, and—where applicable—FDA 510(k) entries for sterile surgical gloves). If a claim can’t be verified via primary sources, it is marked needs verification.

Supplier landscape 2026

Global manufacturers

Global manufacturers are the upstream producers that actually make the gloves (nitrile, latex, vinyl/synthetic formulations). For US hospitals, they matter because they drive:

• Capacity and allocation behavior during demand spikes.
• Formulation stability (the “same SKU, different glove” risk often starts with upstream change control).
• Quality system maturity—which shows up in how quickly they can produce a clean documentation pack (spec sheet, test summaries, lot traceability artifacts).

In practice, many hospitals don’t contract directly with a global manufacturer for every SKU. But even when you buy through a distributor or a GPO award, the manufacturer’s QA discipline and change-control posture still determine whether your receiving team gets consistent cartons and whether infection prevention can sign off on performance.

US distributors and brand-owners

US distributors and brand-owners sit between manufacturers and providers. They may:

• Hold inventory in US warehouses, smoothing lead times.
• Manage packaging, labelling, and assortment (sizes, colors, chemo-rated lines, accelerator-free options).
• Provide service layers hospitals care about: EDI, usage reporting, fill-rate SLAs, and recall communications.

This layer is also where a lot of contract complexity lives. You’ll see tiered pricing, compliance rules, substitutions during shortages, and varying policies on backorders. For IDNs, distributor performance is often the difference between a “great unit price” and a year of emergency buys.

Domestic and nearshore capacity

Domestic and nearshore capacity matters less as a headline (“made here”) and more as a risk-control lever.

• Lead-time and logistics risk: Shorter lanes can reduce exposure to port congestion, ocean delays, and geopolitical shocks.
• Surge response: Regional capacity can be useful when global lanes are constrained.
• Documentation and traceability: Many health systems prioritise suppliers that can support lot traceability and provide documentation quickly when audits or adverse events occur.

A practical way to evaluate this: don’t ask whether a supplier is “domestic.” Ask which parts of the chain are local (manufacturing, finishing/packaging, warehousing) and what their contingency plan is if any node fails.

In this context, suppliers with large-scale global production footprints can still be useful to US hospitals if they support a strong documentation pack and consistent change-control processes.

Example (documentation expectation, not an endorsement): suppliers such as INTCO Medical publish compliance-oriented materials like specifications and certification summaries (see quality assurance & certifications). The procurement point is the standard you should apply to any shortlisted supplier: they should be able to back performance and compliance claims with a clear documentation pack, and they should have change-control processes that prevent “same SKU, different glove” surprises.

Supplier profiles (Top 10, evidence-first)

Below are concise supplier profiles using the same evidence template. Where a point can’t be verified via primary sources quickly, it is marked needs verification.

1) INTCO Medical

• Company & role: manufacturer.
• Product scope: exam gloves (nitrile) supported via product references and procurement content.
• Sterile surgical gloves: Yes (see the evidence links below; confirm SKU-level regulatory requirements for your market).
• Quality & certifications: publishes a dedicated quality assurance & certifications page.
• Evidence: INTCO quality assurance & certifications; INTCO sterile nitrile exam gloves; INTCO surgical gloves overview.

2) Top Glove

• Company & role: manufacturer.
• Product scope: exam gloves (nitrile/latex/vinyl) supported via official product catalogue.
• Sterile surgical gloves: need verification (confirm specific sterile surgical SKUs and their regulatory listings/clearances).
• Quality & certifications: publishes the management system and product certification list.
• Evidence: Top Glove product catalog; Top Glove governance: management systems & product certifications.

3) Ansell

• Company & role: manufacturer/brand.
• Product scope: exam and medical gloves via healthcare catalogue.
• Sterile surgical gloves: GAMMEX surgical glove lines are supported via official product pages.
• Evidence: Ansell medical gloves; Ansell GAMMEX Non-Latex Sensitive surgical gloves.

4) Mölnlycke

• Company & role: brand-owner (hospital surgical focus).
• Product scope: surgical gloves (Biogel family) via official surgical glove portal.
• Exam gloves: needs verification (confirm medical exam glove offerings marketed to US hospitals).
• Evidence: Mölnlycke surgical gloves.

5) Cardinal Health

• Company & role: brand-owner/distributor with surgical glove line.
• Product scope: sterile surgical gloves (Protexis).
• Exam gloves: needs verification (confirm exam glove portfolio pages relevant to hospitals).
• Recall transparency (trust signal): publishes recall notice for select Protexis lots.
• Evidence: Cardinal Health Protexis surgical gloves; Cardinal Health Protexis recall notice.

6) Medline

• Company & role: manufacturer/distributor.
• Product scope: sterile surgical gloves supported via FDA 510(k) record example.
• Exam gloves: needs verification (confirm Medline-branded exam glove product pages).
• Evidence: FDA 510(k) record: Medline surgical gloves (K193217).

7) McKesson

• Company & role: brand-owner/distributor.
• Product scope: exam gloves and surgical gloves categories shown in McKesson Medical-Surgical catalog.
• Regulatory evidence: needs verification at SKU level (catalog confirms availability but not clearance identifiers per item).
• Evidence: McKesson Brand gloves catalog.

8) Hartalega

• Company & role: manufacturer.
• Product scope: exam gloves supported; publishes certifications.
• Regulatory evidence example: FDA 510(k) summary PDF available (example submission; verify the exact SKUs you plan to buy).
• Evidence: Hartalega certifications; FDA 510(k) summary PDF example (K223437).

8) Sempermed / Semperit

• Company & role: brand.
• Product scope: examination gloves and surgical gloves via manufacturer product catalog.
• Quality/compliance: needs verification for ISO 13485 / FDA evidence at SKU level.
• Evidence: Sempermed products.

10) Supermax (Aurelia)

• Company & role: manufacturer/brand.
• Product scope: exam gloves via the Aurelia brand.
• Quality/certification: ISO 13485 is referenced in a public declaration (secondary-hosted; verify with supplier-provided certificate).
• Evidence: Aurelia gloves; Supermax declaration of conformity (ISO 13485 referenced).

Practical note: for sterile surgical gloves, treat FDA 510(k) as SKU-specific. Even within the same brand family, clearances can differ by material, coating, and packaging configuration.

How hospitals source medical gloves

Direct vs distributor routes

There’s no universally “right” route—only the route that matches your risk tolerance and operational needs.

Direct (manufacturer ↔ hospital/health system) can make sense when:

• You need tighter control on spec stability and change notification.
• Volumes justify direct negotiation and structured forecasting.
• You have the internal bandwidth to manage supplier qualification, inbound QC, and performance reviews.

Distributor routes can make sense when:

• You need inventory buffering and faster replenishment.
• You want consolidated freight, fewer invoices, and more flexible order minimums.
• You’re standardizing across many sites and need consistent service plus usage reporting.

A common hybrid: keep high-volume exam gloves on a primary distributor lane, and establish a secondary direct or alternate distributor lane for surge coverage.

Group purchasing arrangements and tiering

Many health systems use group purchasing arrangements (for example, GPOs in the United States) to standardize SKUs and negotiate pricing. The benefit is leverage and standardization; the risk is overconcentration.

What to watch in 2026:

• Tiering and compliance: Tiered pricing can reward standardization, but it also penalizes legitimate clinical exceptions unless you have a clean exception workflow.
• Substitution rules: Understand whether contracts allow “equivalent” substitutions during shortages and what “equivalent” means operationally (material, thickness band, texture, AQL, chemo rating).
• Documentation access: Your lane is only as good as your ability to obtain traceability artifacts and documentation quickly.

Multi-site governance and service levels

Large health systems often win or lose glove programs in the last mile:

• Service-level agreements (SLAs): fill rate, backorder communication, and allocation rules.
• SKU governance: who can add a glove SKU, who can override, and how clinical trials are documented.
• Cross-facility visibility: redistribution between sites can reduce emergency buys, but only if the data is real-time.

Treat supplier selection as a program: supplier + channel + internal compliance process.

Compliance and standards

FDA device and 510(k)

US hospitals generally treat medical exam gloves as regulated medical devices, which makes documentation and labeling discipline non-negotiable. The FDA’s overview of Medical Gloves is a useful baseline for how the agency frames glove use, labeling, and safety expectations.

From a procurement standpoint, the key question is not “do they say medical grade?” but “can they support the regulatory posture and evidence the facility needs?” In practice, that includes confirming the appropriate FDA status (including FDA 510(k) exam gloves requirements where applicable), ensuring labeling is clear for latex vs non-latex, and being able to support recalls with traceability.

ASTM anchors: D6319, D6978, D3577

ASTM standards function as shared reference points when you write requirements and compare products.

• ASTM D6319 is commonly referenced for nitrile examination gloves.
• ASTM D6978 is the common anchor for chemotherapy-rated gloves (permeation resistance requirements for certain drugs).
• ASTM D3577 is associated with rubber surgical gloves.

Your contract language should reference the relevant standard(s) for the intended use, but your qualification workflow should go further: confirm what was tested, when it was tested, and whether the results apply to the exact SKU and lot ranges you will receive.

A practical way to write requirements so they’re auditable is to translate those standard IDs into plain-language spec lines (material, thickness band, texture, length) and tie them to documentation requests—for example, “Conforms to ASTM D6319 nitrile exam gloves specification; provide lot-level CoA and the test summary used to support conformance.”

Documentation: AQL, CoA, traceability

Hospitals don’t buy “gloves.” They buy gloves plus an evidence trail.

Key artifacts to require:

• AQL (Acceptance Quality Level): This is a statistical sampling standard used to manage defect tolerance (commonly discussed for pinhole defects). Your internal standards may vary by use case, but the operational point is consistent: align the AQL target to clinical risk and enforce it through documentation and incoming QC.
• CoA (Certificate of Analysis): A batch/lot-level document that ties test results to a specific production lot.
• Traceability: Lot/batch identifiers on cases and inner boxes that allow you to isolate an issue quickly.

When drafting your RFP language, be explicit (and consistent) about the AQL you require for each SKU class. Many teams include a plain-language requirement such as “AQL 2.5 medical gloves (pinhole defects) or better, with lot-level documentation available on request,” then validate by incoming sampling and trend tracking.

If you want a practical checklist for what to request before pricing negotiations, use a procurement-oriented document pack request similar to Medical grade gloves supplier checklist—regardless of which supplier you choose.

Pro Tip: Make “change control” contractual. If a supplier changes formulation, thickness range, or packaging, require written notice and re-qualification triggers.

Performance and fit

Material and tactility factors

Material choice is still the first-order decision for most hospitals:

• Nitrile is widely used as the default for exam workflows because it’s a strong synthetic barrier and avoids natural rubber latex proteins.
• Latex may still appear in certain contexts where tactility matters and allergy controls are in place.
• Vinyl / synthetic blends can have a place in low-risk, short-duration tasks—but the decision should be driven by failure modes (tearing, grip loss, donning issues) and not just price.

Performance isn’t a single number. For user acceptance and compliance, evaluate:

• grip (dry/wet), texture pattern, and fingertip precision
• tear resistance in real workflows
• odor/residue concerns
• packaging usability (box design that reduces waste)

For a practical overview of how options map to use cases, see Choosing exam gloves: available options as one example of how suppliers frame material tradeoffs.

Chemo-rated and accelerator-free options

Two specialty requirements that commonly trigger SKU proliferation:

• Chemo-rated gloves: If oncology or hazardous-drug handling is in scope, require explicit chemo claims tied to the right standard (commonly ASTM D6978) and request the permeation documentation that corresponds to your drug list. If your RFP uses exact language, you may reference “ASTM D6978 chemotherapy gloves” to avoid ambiguity about the intended performance claim.
• Accelerator-free options: For staff with sensitization concerns, accelerator-free nitrile can reduce dermatitis risk—but it may change feel, elasticity, and cost. Treat it as a separate clinical evaluation, not a silent substitution.

Sizing, donning, and comfort

Hospitals often underestimate how much fit drives compliance.

Operationally:

• standardise on a size curve that actually fits your workforce (including XS and XL availability)
• run trials across roles (nursing, EVS, lab, phlebotomy) because failure modes differ
• measure donning time and failure rate per shift during pilots

Key Takeaway: A supplier that can hit an AQL target but can’t deliver consistent sizing across lots will still create hidden costs through reorders, staff complaints, and off-contract purchases.

Total cost and risk

Landed cost under tariff scenarios

In 2026, landed cost is not just the unit price. It’s unit price plus:

• duties/tariffs and country-of-origin impact
• freight volatility (spot vs contract)
• warehousing and distribution fees
• expediting costs when backorders hit

Build scenarios with your finance team: “base,” “high freight,” and “tariff shock.” Then compare suppliers on their ability to stabilise landed cost, not merely quote low pricing.

Contracting, rebates, and compliance

Your contract is part of your quality system.

• Tie price breaks and rebates to measurable behaviours you can verify (fill rates, documentation turnaround times, notice periods for substitutions).
• Define what happens when service levels fail: credits, alternate sourcing rights, or exit clauses.
• Align contract compliance with clinical acceptance: if staff hate the glove, they’ll route around the contract.

Waste, sustainability, and hidden costs

Hidden costs are where glove programs quietly lose money:

• box and case design that increases glove waste
• high tear rates leading to double-gloving or frequent changes
• SKU sprawl (too many similar SKUs increases training burden and picking errors)
• disposal costs and sustainability reporting overhead

Track these as KPIs alongside price: gloves used per patient day (where appropriate), failure rate, and percent off-contract purchases.

Resilience and ESG

Dual-sourcing and buffers

If the last few years taught anything, it’s that resilience must be designed.

Use CDC’s framing of PPE stress (conventional → contingency → crisis) as a planning lens when you set buffer targets and shortage playbooks; the agency notes that as supply stabilizes, facilities should return to conventional practices (see CDC guidance on conserving PPE during shortages).

In procurement terms, aim for:

• dual sourcing for critical glove categories (primary + secondary)
• pre-qualified alternates with samples and documentation already on file
• buffers sized to variability (not a one-size “X days” rule)

Geographic diversification and logistics agility

Diversification can happen at multiple layers:

• manufacturing geography (don’t concentrate all volume in a single region)
• logistics lanes (alternate ports, carriers, and domestic DCs)
• packaging/labeling nodes (a small bottleneck can stop the whole flow)

Agility is also contractual: define how allocations are handled in shortages and what communication cadence you’ll get.

Traceability, labour risk, and EPP goals

ESG expectations in 2026 increasingly intersect with operational risk:

• Traceability supports recall response and can support responsible sourcing verification.
• Labour risk controls (supplier code of conduct, audits) reduce reputational and disruption risk.
• EPP goals (environmentally preferable purchasing) often require documentation—materials disclosure, packaging details, and evidence behind sustainability claims.

Treat ESG as part of supplier qualification, not a marketing checkbox.

Limitations and verification (read before using the rankings)

Supplier capabilities, product SKUs, and regulatory status can change. Before contracting, verify claims against primary evidence (e.g., FDA guidance and supplier-provided documentation such as lot-level CoA, traceability labels, and change-control notices).

For context, the FDA explains how it regulates medical gloves in FDA: Medical Gloves. For sterile surgical gloves, treat 510(k) clearance as SKU-specific (material, coating, and packaging configuration can affect the cleared device).

Frequently asked questions

Are medical examination gloves and surgical gloves regulated the same way?

Not always. Requirements vary by country/region and by intended use (exam vs sterile surgical). Start with your local regulator’s guidance, then verify the exact SKU’s labelling, documentation pack, and (where applicable) premarket clearance/registration.

What documents should I request from a shortlisted glove supplier?

At minimum:

• product specification / technical data sheet
• applicable standards claims (e.g., ASTM references where used)
• lot/traceability labeling examples (case + inner box)
• lot-level documentation availability (e.g., CoA)
• change-control policy (how formulation/packaging changes are communicated)
• recall/field action process and contact

How should I validate “sterile” claims?

Treat sterility as a package-and-process claim, not just a product label. Ask for the sterilization method, packaging configuration, and the supplier’s evidence that the sterile barrier system is maintained through shelf life and transport. Also confirm what your local regulator requires for sterile surgical gloves.

What does AQL mean for medical gloves?

AQL (Acceptance Quality Level) is a statistical sampling concept used to manage defect tolerance (often discussed for pinhole defects). It’s not the only quality measure, but it’s a common procurement screen. Align the target AQL with clinical risk and validate it via documentation and incoming QC.

How many suppliers should a hospital keep qualified?

For critical glove categories, many procurement teams aim for at least two qualified sources (primary + secondary), with samples and documentation already on file for alternates. The right number depends on your usage volumes, logistics risk, and your ability to manage SKU governance.

Is “nitrile” always the best choice?

Not necessarily. Nitrile is widely used for exam workflows, but sterile surgical needs, sensitization concerns, and specific task requirements may call for other materials. Use clinical trials, failure-mode tracking, and documentation-based qualification to decide.

Why do some items in the shortlist table say “needs verification”?

Because this guide prioritizes publicly verifiable evidence. If a claim (for example, whether a supplier offers a specific sterile surgical SKU in your market) can’t be confirmed via primary sources, it’s marked “needs verification” so teams don’t treat it as a confirmed fact.

• Selecting resilient, compliant suppliers in 2026 means evaluating the full ecosystem: manufacturer capability, distributor execution, GPO/IDN contract mechanics, and your internal governance.
• Anchor decisions in documentation (FDA status, relevant ASTM references, AQL/CoA/traceability) and in real-world trials for fit and failure modes.
• Build TCO models that include freight, substitutions, waste, and off-contract leakage—and pair them with a resilience plan (dual sourcing, buffers, diversified lanes).
• Immediate next steps to align contracts, testing, and inventory buffers:
  • Standardise a one-page requirements sheet (materials, sizing, special needs like chemo-rated or accelerator-free).
  • Request the documentation pack and confirm lot traceability artifacts before final pricing.
  • Run a structured pilot across roles and sites, capturing failure rate and user acceptance.
  • Write service levels and change-control triggers into contracts, then set buffer targets tied to volatility.